



THIRD ROCK VENTURES EXPANDS TEAM WITH BIOTECH VETERANS

New Roles Deepen Expertise in Entrepreneurship, Scientific Evaluation, Clinical Development and Talent Acquisition

BOSTON, Mass., July 21, 2009—Third Rock Ventures, L.L.C., a venture capital firm focused on launching leading life sciences companies, today announced the appointment of Philip R. Reilly, M.D., as Venture Partner, Gregory L. Verdine, Ph.D., as Venture Partner, and Craig M. Greaves as Recruiting Partner.

“We are excited to broaden the capabilities of our cross-functional team at Third Rock Ventures team with such seasoned and talented leaders,” said Kevin Starr, partner of Third Rock Ventures. “As Third Rock Ventures implements our unique brand of life sciences venture investing, we are delighted to add Phil, Greg and Craig to our team to provide their experience and unique capabilities in our core competencies – entrepreneurial innovation, scientific leadership and talent acquisition – that are so vital to Third Rock Ventures and our portfolio companies as we launch, build and operate great life sciences companies.”

Third Rock Ventures employs a unique model in which its team actively collaborates with entrepreneurs, initially filling key active management roles as needed to architect the right vision, operations, and culture to create companies that will make a difference in people’s lives and ultimately deliver exceptional value.

Philip R. Reilly, M.D., is an accomplished entrepreneur and renowned clinician who has dedicated his career to pioneering new treatments for genetic disorders. From 2000 to 2006 Dr. Reilly served as CEO and Chairman of the Board of Interleukin Genetics, Inc, a publicly traded biotech company (AMEX:ILI) which focused on developing DNA based risk tests associated with variations in the interleukin-1 gene. Prior to joining Interleukin Genetics, Dr. Reilly was the Executive Director of the Eunice Kennedy Shriver Center for Mental Retardation, Inc. a not-for-profit organization in Massachusetts, a position he had held since 1990. The author of six books and author or co-author of more than 100 articles in scholarly journals, Dr. Reilly has held numerous teaching positions including assistant professor at Tufts University School of Medicine, assistant professor of Neurology at Harvard Medical School, and adjunct professor of both Legal Studies and Biology at Brandeis University. He is currently a trustee of Cornell University and was a visiting professor at Cornell in the fall of 2008. Dr. Reilly was twice (2000 and 2003) president of the American Society of Law, Medicine, and Ethics, an organization that numbers several thousand members. From 1994 to 1997, he served on the board of directors of the American Society for Human Genetics. Board certified in internal medicine and clinical genetics, he earned his M.D. from Yale University, his J.D. from Columbia University, and is a member of the Massachusetts Bar.

As a Venture Partner at Third Rock Ventures, Dr. Reilly will support the firm’s founding and advancement of new ventures, with a particular focus on seeking to nurture and grow transformational companies dedicated to breakthrough treatments for genetic disorders. Additionally, he will support the strategic efforts across the firm’s entire portfolio, bringing his unique entrepreneurial, clinical, and scientific insights to the firm’s diverse portfolio.

Greg Verdine, Ph.D., is a leading figure in the field of chemical biology and an experienced drug discovery entrepreneur. He is presently the Director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute, and is a Harvard College Professor and the Erving Professor of Chemistry at Harvard University. He holds academic appointments within various departments at Harvard in Stem Cell and Regenerative Biology (SCRB), Chemistry and Chemical Biology (CCB), and Molecular and Cellular Biology (MCB), as well as at the Dana-Farber Cancer Institute in the Department of Cancer Biology. His Dana-Farber research effort aims to discover entirely new molecular classes of drugs to tackle so-called “undruggable” targets, while his work in the Harvard Faculty of Arts and Sciences focuses on understanding fundamental aspects of DNA damage recognition and repair.

of Variagenics, Inc., and he co-founded Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, and Ontorii Pharmaceuticals. He currently serves as Scientific Advisor to the Board of Directors of the Ibusuki Medipolis Research Institute (Kagoshima Prefecture, Japan), in addition to serving on the Board of Reviewers of the Bill and Melinda Gates Foundation, the Board of Scientific Consultants of the Memorial Sloan Kettering Research Institute, and the Scientific Advisory Board of the SMA Foundation.

As a Venture Partner at Third Rock Ventures, Dr. Verdine will support the firm's science, planning and analysis of potential new entrepreneurial ventures. Additionally, he will support the early-stage planning efforts for the firm's entire portfolio, bringing his unique scientific insights to enrich the firm's strategies for portfolio companies.

Craig Greaves has over 15 years of experience attracting and growing outstanding teams at leading Boston-area biotechnology companies. Most recently, he was Director, Talent Acquisition at Cubist Pharmaceuticals where he led the team that was responsible for the entire company's recruiting. In addition, he was Director of Employment at Biogen Idec where he was responsible for all domestic recruiting activities in three locations, including executive search firm selection and management, employment branding, communications, and full time and temporary hiring. At Biogen Idec, he managed a staff of more than 30 human resource professionals. Mr. Greaves transitioned to Biogen Idec from Biogen, where he worked in various recruiting and human resource roles over a nine-year period during which Biogen grew from a domestic research organization of 350 employees in 1994 to a fully integrated commercial biotechnology company with 2,700 employees located in 20 countries in 2003.

As Recruiting Partner at Third Rock Ventures, Mr. Greaves will lead all efforts for talent acquisition and resource allocation at Third Rock Ventures and in support of its portfolio companies. For Third Rock Ventures, Mr. Greaves will recruit entrepreneurs-in-residence and associates as well as advisors and consultants. With portfolio companies, he will help identify recruiting needs based on resource planning and allocation results, focusing on supporting recruitment of key leadership positions for portfolio management teams.

About Third Rock Ventures

Third Rock Ventures L.L.C. is a premier venture firm focused on life sciences, investing and launching companies that make a difference in people's lives. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for a rapidly-growing and highly-successful life sciences company. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance. For more information, please visit www.thirdrockventures.com.

Contact

Barbara Yates
Yates Public Relations
781-258-6153

###